Small-cell carcinoma of the esophagus (SCCE) is a rare and rapidly progressive malignant tumor with an extremely unfavorable prognosis. We report a case of long-term survival and review similar cases in the literature. An 84-year-old Japanese woman visited a clinic complaining of tarry stools. Type-1 tumor was detected in the left posterior wall of the middle thoracic esophagus on endoscopic examination, and the pathological diagnosis following immunohistochemical examination was SCCE. Chemoradiotherapy was adopted after taking the characteristics of poor prognosis, rapid progression, and patient age into consideration. Chemoradiotherapy comprised 56 Gy of irradiation over 43 days and two courses chemotherapy with cisplatin and vincristine. Therapeutic effect was evaluated as complete response after endoscopic examination and computed tomography at one month after treatment. No recurrence or metastasis has been identified as of more than five years after achieving complete response, with endoscopic examination every six months and computed tomography every three months. To date, long-term survival has only been reported in octogenarian patients with SCCE, and the present case describes the oldest patient for whom successful radical therapy has been reported.
Introduction
Small-cell carcinoma of the esophagus (SCCE) is an uncommon disease, accounting for 0.05-3.1% of all esophageal cancers. [1] [2] [3] [4] [5] [6] [7] In addition, SCCE displays aggressive progression and an extremely unfavorable prognosis. 1-4 6 8-25 McKeown first reported two cases of SCCE in 1952. 26 Few reports of large series have been reported to date because of the rarity of this entity. Optimal treatment for this tumor has yet to be defined, because of the lack of any comprehensive description of SCCE, and surgery, chemotherapy, radiotherapy, or a combination might be performed empirically, with no promise of efficacy.
Similarly, the epidemiological risk factors for SCCE remain uncertain. Alcohol and smoking are commonly regarded as potential risk factors, but no clear correlations have been demonstrated in previous epidemiological studies. 6 17 27 We report an octogenarian patient with SCCE who has achieved complete remission lasting more than 1 
Similarly, the epidemiological risk factors for SCCE remain uncertain. Alcohol and smoking are commonly regarded as potential risk factors, but no clear correlations have been demonstrated in previous epidemiological studies. 6 17 27 We report an octogenarian patient with SCCE who has achieved complete remission lasting more than five years after receiving chemoradiotherapy (CRT) using cisplatin (CDDP) and vincristine (VCR). According to our review of the literature, this represents the oldest patient with SCCE to show long-term survival after radical CRT.
Case Report
An 84-year-old Japanese woman visited a clinic complaining of tarry stools. She had been receiving treatment for hypertension and dilated cardiomyopathy for 6 years. A type-1 tumor was identified on upper gastrointestinal series and endoscopic examination on the left posterior wall of the middle thoracic esophagus, 28-32 cm from the incisors (Fig. 1a, 1b) . The tumor was almost entirely covered with white film. The small round tumor cells showed a high nucleus-cytoplasm ratio and hyperchromatic nuclei. Part of the tumor had become necrotic, and no intercellular bridges or tubular formations were apparent from biopsy specimens. Tumor cells were negative for leukocyte common antigen, but positive for epithelial membranous antigen, chromogranin A, neuron-specific enolase, synaptophysin and CD56 on immunohistochemical staining (Fig. 1c) , compatible with the diagnosis of small-cell carcinoma. In addition, abdominal computed tomography (CT) revealed no lymph node or distant metastases. The tumor was classified as T2N0M0 stage Ib according to the TNM Classification of malignant tumors and limited disease (LD). CRT, but not surgery, was adopted after taking into consideration the surgical invasiveness of esophagectomy, the unfavorable prognosis of SCCE, and the age and general condition of the patient. The total amount of irradiation was 56 Gy over 43 days, and the 2 courses of chemotherapy administered comprised CDDP at 80 mg/ body/day on day 1 and VCR at 100 g/body/day on days 1-3. One month after completing CRT, the type-1 tumor had disappeared, and scar tissue was evident in its place, and no Lugol unstained area was apparent. No metastatic lesion could be detected on CT. Follow-up CT has been performed every 3 months for more than 5 years, but no recurrences or metastases have been detected.
Discussion
Extrapulmonary small cell carcinoma is rare, accounting for approximately 2.5% of all small-cell carcinomas, 28 and the esophagus is the most common location in the digestive system. 29 SCCE is a rapidly progressive disease exhibiting an extremely unfavorable prognosis. The overall median survival time (MST) is 3.4-19 months, 1-4 6 8-25 and the 5-year survival rate is 6.7-15.4%. 2 10 12 23 Significant differences in MST and 5-year survival rate have been reported between patients with LD and extensive disease (ED). According to the Veterans' Administration Lung Study Group, LD is defined as tumor confined within a localized anatomical region with or without regional lymph node metastasis, while ED is defined as tumor extending beyond the loco-regional boundaries. MST for LD and ED is reported to be 4-62 months and 2-11 months, respectively.
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The 5-year survival rates are reportedly 19-24% for LD and 2.7% for ED ( Table 1) . 2 20 Standard treatment for SCCE has yet to be established. Surgery, radiotherapy, and chemotherapy have been adopted alone or in combination on an empirical basis. However, the role of surgery leaves much room for discussion. Twenty-three cases with long-term (more than 5-year) survival have been reported in the literature and are summarized in Table 2 . Among these, a small number of patients were treated using surgery alone.
11 24 32 Some authors have recommended surgery for patients with LD, 8 and Lv, et al. 2 reported MST analysis based on the therapeutic method. However, their conclusions were controversial, with Chen, et al. reporting surgery with chemotherapy as an independent prognostic factor, 10 and Lv reporting chemotherapy as an independent prognostic factor. 2 Multidrug combination chemotherapy seems effective with or without surgery. Vos reported that chemotherapy prolonged MST from 9.5 months (interquartile range [IQR], 6-14 months) to 6 months (IQR, 4-7 months) in ED, and concurrent CRT prolonged MST from 36 months (IQR, 14-93 months) to 11 months (IQR, 9-15 months) in LD compared with nonconcurrent chemotherapy and radiotherapy. 9 Although various combinations of drugs have been applied, of all the combinations used for patients who survived more than 5 years, the most common have been CDDP + VP-16-based regimens commonly used for small-cell carcinoma of the lung (SCCL), which closely resembles SCCE in clinical and histological features ( Table 2) . Regimens based on CDDP are thus often used for SCCE. 18 33 Yau, et al. suggested that chemotherapy with radiotherapy should not be recommended as the primary treatment for SCCE until randomized trials have been performed. 3 In our case, CRT was performed according to a regimen for SCCL, using CDDP and VCR. We thought that surgery might prove too invasive, as the patient was 84 years old, although surgery has priority for achieving local control of SCCE. In addition, gastric store can be preserved because stomach rolls do not have to be used for reconstruction after esophagectomy. This means that quality of life in terms of eating ability after CRT is superior to that after surgery. From the previous report, surgical trends for the selection of relatively younger patients with prolonged survival are summarized in Table 2 . The role of surgery is controversial, as mentioned above, and nonsurgical therapies should be considered a valid treatment for such high-risk patients. In terms of the chemotherapeutic regimen, we recommend CDDP + VP-16-based regimens as used for SCCL, based on the review of SCCE cases showing long-term survival. Of interest is the fact that patients with SCCE who underwent chemotherapy with CDDP + VP-16 (but not with 5FU-based regimens) exhibited prolonged survival, as listed in Table 2 . While randomized control studies are not likely to prove practical given the rarity of this pathology, further studies are required to establish standard therapy for SCCE.
